Allergic conditions linked to higher risk of Long-COVID, study finds

NewsGuard 100/100 Score

In an analysis of published prospective studies of people of all ages with confirmed SARS-CoV-2 infection who were followed for at least 12 months, pre-existing allergic conditions were linked to higher risks of experiencing long-term symptoms associated with COVID-19, or Long-COVID.

The analysis, which is published in Clinical & Experimental Allergy, identified 13 relevant studies (with a total of 9,967 participants) published between January 1, 2020 and January 19, 2023.

Although the data as a whole from the studies suggested that individuals with asthma or rhinitis might be at increased risk of Long-COVID after SARS-CoV-2 infection, the evidence for these associations was very uncertain. Therefore, more robust epidemiological research is needed to clarify the role of allergy in the development of Long-COVID.

We need a better, harmonized definition of what is considered Long-COVID for epidemiological studies of this sort. Regardless we will be updating our analysis once further studies have been published in the next few months."

Christian Apfelbacher, PhD, corresponding author, Institute of Social Medicine and Health Systems Research, Germany

Source:
Journal reference:

Wolff, D., et al. (2023) Allergic diseases as risk factors for Long-COVID symptoms: Systematic review of prospective cohort studies. Clinical & Experimental Allergy. doi.org/10.1111/cea.14391.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New class of antiviral drugs could shield against future viral outbreaks